Answers are grounded in this paper and cite their sources.
Coproporphyrin (CP)-I and CP-III are the markers of organic anion-transporting polypeptides' (OATPs) activities, and they are porphyrin metabolites that originate from heme synthesis.Furthermore, CP-I and CP-III, which are OATP1B endogenous metabolites, have gradually attracted the attention of scientists and researchers in recent years.Previous studies have also observed CP-I and CP-III levels as clinical biomarkers for predicting OATP1B inhibition in drug-drug interaction studies.To establish an accurate ultra-high performance liquid chromatography-mass spectrometry method for the quantitation of CP-I and CP-III, we reviewed previous methodological publications and applied them to a clinical pharmacology study using a human urine matrix.We used 13.25 M formic acid as a working solution for internal standards (CP-I 15 N 4 and CP-III d 8 ) to avoid isobaric interference.The calibration curve showed good linearity in the range of 1-100 ng/mL, with a correlation coefficient (R 2 ) higher than 0.996 in each validation batch.Both the between-run and within-run assays achieved good precision and accuracy, and we found that both CP-I and CP-III were stable in the prestudy validation.The method exhibited suitable dilution integrity, allowing for the re-analysis of samples with concentrations exceeding the upper limit of quantification through dilution.Overall, the application of the described method in a clinical study revealed that it can be utilized effectively to monitor drug-drug interactions mediated by OATP1B.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: